Stock listing
IMTX Stock Price, News, Filings & Events — Immatics N.v.
Selected listing: IMTX · NASDAQ · USD · US
This page tracks Immatics N.v.'s IMTX:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following IMTX:NASDAQ. IMTX:NASDAQ is the stock-level entry point for investors researching Immatics N.v., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Immatics N.V. is a public company traded under the ticker IMTX in the American market. The company has a market capitalization of approximately $1.22 billion. Immatics focuses on developing innovative cancer immunotherapies.
- Ticker
- IMTX:NASDAQ
- Asset type
- Stock
- Market cap
- $1.22B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
Immatics N.v. IMTX:NASDAQ stock context
This page tracks Immatics N.v.'s IMTX:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following IMTX:NASDAQ. IMTX:NASDAQ is the stock-level entry point for investors researching Immatics N.v., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Immatics N.V. is a public company traded under the ticker IMTX in the American market. The company has a market capitalization of approximately $1.22 billion. Immatics focuses on developing innovative cancer immunotherapies.
Latest news from Immatics N.v.
Immatics Announces $150 Million Underwritten Offering
August 25, 2026
Immatics N : Announces Second Quarter 2026 Financial Results and Business Update
August 18, 2026
Immatics Announces Second Quarter 2026 Financial Results and Business Update
August 18, 2026
Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Cancer Vaccine Candidate ITI-5000
July 20, 2026
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
July 17, 2026
Research Immatics N.v.
Immatics N.v. investor report
Review AI stock analysis and investor report context for IMTX:NASDAQ.
Immatics N.v. company profile
View the public company page for Immatics N.v. on 6ix.
Immatics N.v. news
Read company news and market updates connected to Immatics N.v..
Immatics N.v. investor events
Find investor webinars, events, and replay context for Immatics N.v..
Alternate listings
4A3:TRADEGATE
DE · EUR
Alternate listing for Immatics N.v.; the primary context on this page is IMTX:NASDAQ.
4A3:FWB
DE · EUR
Alternate listing for Immatics N.v.; the primary context on this page is IMTX:NASDAQ.
4A3:GETTEX
DE · EUR
Alternate listing for Immatics N.v.; the primary context on this page is IMTX:NASDAQ.
A2P72S:LSX
DE · EUR
Alternate listing for Immatics N.v.; the primary context on this page is IMTX:NASDAQ.
A2P72S:LS
DE · EUR
Alternate listing for Immatics N.v.; the primary context on this page is IMTX:NASDAQ.
4A3:SWB
DE · EUR
Alternate listing for Immatics N.v.; the primary context on this page is IMTX:NASDAQ.
IMTX:BOATS
US · USD
Alternate listing for Immatics N.v.; the primary context on this page is IMTX:NASDAQ.
4A3:DUS
DE · EUR
Alternate listing for Immatics N.v.; the primary context on this page is IMTX:NASDAQ.
4A3:HAM
DE · EUR
Alternate listing for Immatics N.v.; the primary context on this page is IMTX:NASDAQ.
4A3:MUN
DE · EUR
Alternate listing for Immatics N.v.; the primary context on this page is IMTX:NASDAQ.